Crixivan Patent Expiration

Crixivan is a drug owned by Merck Sharp And Dohme Corp. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 10, 2021. Details of Crixivan's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6689761 Combination therapy for HIV infection
Feb, 2021

(3 years ago)

Expired
US6645961 Dry granulation formulation for an HIV protease inhibitor
Mar, 2018

(6 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Crixivan and ongoing litigations to help you estimate the early arrival of Crixivan generic.

Crixivan's Litigations

Crixivan been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 22, 2001, against patent number US6689761. The petitioner , challenged the validity of this patent, with CHODAKEWITZ et al as the respondent. Click below to track the latest information on how companies are challenging Crixivan's patents.

Last updated on December 3, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6645961 June, 2001 Decision
(27 Mar, 2002)
LUI et al
US6689761 March, 2001 Decision
(25 May, 2001)
CHODAKEWITZ et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Crixivan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Crixivan's family patents as well as insights into ongoing legal events on those patents.

Crixivan's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Crixivan's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 10, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Crixivan Generics:

There are no approved generic versions for Crixivan as of now.





About Crixivan

Crixivan is a drug owned by Merck Sharp And Dohme Corp. It is used for managing HIV infection when used in combination with other antiretroviral agents. Crixivan uses Indinavir Sulfate as an active ingredient. Crixivan was launched by Merck Sharp Dohme in 2000.

Approval Date:

Crixivan was approved by FDA for market use on 19 April, 2000.

Active Ingredient:

Crixivan uses Indinavir Sulfate as the active ingredient. Check out other Drugs and Companies using Indinavir Sulfate ingredient

Treatment:

Crixivan is used for managing HIV infection when used in combination with other antiretroviral agents.

Dosage:

Crixivan is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 200MG BASE CAPSULE Discontinued ORAL
EQ 333MG BASE CAPSULE Discontinued ORAL
EQ 100MG BASE CAPSULE Discontinued ORAL
EQ 400MG BASE CAPSULE Discontinued ORAL